Market Cap 6.87M
Revenue (ttm) 1.63M
Net Income (ttm) -17.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,077.30%
Debt to Equity Ratio -0.04
Volume 10,693,900
Avg Vol 1,295,886
Day's Range N/A - N/A
Shares Out 1.01M
Stochastic %K 74%
Beta 2.64
Analysts Strong Sell
Price Target $15.00

Company Profile

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metast...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 9472 4101
Address:
Three International Towers, Level 24 300 Barangaroo Avenue, Sydney, Australia
BeeHawk
BeeHawk Jul. 10 at 6:57 AM
$KZIA we have a potential multi billion dollar drug that can save lives. If Kazia can survive financially this will explode in valuation. Or the company will fail and another will run with it. But regardless, this is a breakthrough drug and it will benefit society. So as a very long term long, I’ll keep holding to the end.
1 · Reply
LabMan
LabMan Jul. 10 at 4:01 AM
$KZIA In earlier research - Highly aggressive cancer stem cell phenotypes, (a cancer cell type), develop cancer drug resistance signatures. PI3K–mTOR blockade acts upstream of these damaged pathway mechanisms, to inhibit (repair/restrict ) this breakdown. Thus, pAX overcomes immunotherapy resistance to reduce primary tumor burden, circulating tumor cells, and direct and indirect indicators of metastasis, with a favorable toxicity profile. Gene expression analyses show that paxalisib profoundly affects the immune microenvironment in tumors, reducing adaptive immune phenotypes, associated with immunotherapy resistance. It would seem apparent, and as stated this novel new combo treatment may offer therapeutic direction in PI3K / mTOR dysregulated solid tumor cancer. This is a high impact breakthrough in cancer immunotherapy treatment.
0 · Reply
Rinnekin
Rinnekin Jul. 9 at 9:41 PM
1 · Reply
BreakoutBullz
BreakoutBullz Jul. 9 at 9:24 PM
Have a great evening, everyone!💰 Link in bio! See you on tomorrow at 4 AM ET! 🕓 Some of our plays from today! 🔥💰🎯 $EVOK $SUGP $CLDI $PROK $KZIA
0 · Reply
BRDUPO
BRDUPO Jul. 9 at 8:19 PM
$KZIA Liquidated me long at $7.80 off $8.80 and then proceeded up into $9S. after holding consolidation all day. Weird
1 · Reply
algo888
algo888 Jul. 9 at 8:14 PM
$KZIA from 5.70 low yesterday to $15.54 High today ... saw it but did not act on it yesterday...
0 · Reply
McGrupp
McGrupp Jul. 9 at 7:56 PM
1 · Reply
VMAESA
VMAESA Jul. 9 at 7:54 PM
$KZIA Simple stress free 12+ entry short paid thousands of my discord members today
0 · Reply
FlowerPower80
FlowerPower80 Jul. 9 at 7:27 PM
$KZIA The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction in circulating tumor cells (CTCs) and a notable decrease in CTC clusters.
0 · Reply
j2012
j2012 Jul. 9 at 6:07 PM
$KZIA needs to breakthrough 9.26 then $11 is easy to $15+
0 · Reply
Latest News on KZIA
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Sep 12, 2024, 7:30 AM EDT - 10 months ago

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER


KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Jan 18, 2024, 7:30 AM EST - 1 year ago

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS


KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Nov 20, 2023, 4:30 PM EST - 1 year ago

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION


Kazia announces voluntary delisting from ASX

Oct 11, 2023, 7:01 AM EDT - 1 year ago

Kazia announces voluntary delisting from ASX


KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS

Jan 16, 2023, 7:01 AM EST - 2 years ago

KAZIA RAISES A$4.5 MILLION TO PROGRESS R&D PROGRAMS


BeeHawk
BeeHawk Jul. 10 at 6:57 AM
$KZIA we have a potential multi billion dollar drug that can save lives. If Kazia can survive financially this will explode in valuation. Or the company will fail and another will run with it. But regardless, this is a breakthrough drug and it will benefit society. So as a very long term long, I’ll keep holding to the end.
1 · Reply
LabMan
LabMan Jul. 10 at 4:01 AM
$KZIA In earlier research - Highly aggressive cancer stem cell phenotypes, (a cancer cell type), develop cancer drug resistance signatures. PI3K–mTOR blockade acts upstream of these damaged pathway mechanisms, to inhibit (repair/restrict ) this breakdown. Thus, pAX overcomes immunotherapy resistance to reduce primary tumor burden, circulating tumor cells, and direct and indirect indicators of metastasis, with a favorable toxicity profile. Gene expression analyses show that paxalisib profoundly affects the immune microenvironment in tumors, reducing adaptive immune phenotypes, associated with immunotherapy resistance. It would seem apparent, and as stated this novel new combo treatment may offer therapeutic direction in PI3K / mTOR dysregulated solid tumor cancer. This is a high impact breakthrough in cancer immunotherapy treatment.
0 · Reply
Rinnekin
Rinnekin Jul. 9 at 9:41 PM
1 · Reply
BreakoutBullz
BreakoutBullz Jul. 9 at 9:24 PM
Have a great evening, everyone!💰 Link in bio! See you on tomorrow at 4 AM ET! 🕓 Some of our plays from today! 🔥💰🎯 $EVOK $SUGP $CLDI $PROK $KZIA
0 · Reply
BRDUPO
BRDUPO Jul. 9 at 8:19 PM
$KZIA Liquidated me long at $7.80 off $8.80 and then proceeded up into $9S. after holding consolidation all day. Weird
1 · Reply
algo888
algo888 Jul. 9 at 8:14 PM
$KZIA from 5.70 low yesterday to $15.54 High today ... saw it but did not act on it yesterday...
0 · Reply
McGrupp
McGrupp Jul. 9 at 7:56 PM
1 · Reply
VMAESA
VMAESA Jul. 9 at 7:54 PM
$KZIA Simple stress free 12+ entry short paid thousands of my discord members today
0 · Reply
FlowerPower80
FlowerPower80 Jul. 9 at 7:27 PM
$KZIA The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction in circulating tumor cells (CTCs) and a notable decrease in CTC clusters.
0 · Reply
j2012
j2012 Jul. 9 at 6:07 PM
$KZIA needs to breakthrough 9.26 then $11 is easy to $15+
0 · Reply
jacckkmm
jacckkmm Jul. 9 at 5:34 PM
$KZIA one patient becomes 2 .. then 20… 200 .. then $$$$$ Rate opportunity here .. for humanity and investors..
0 · Reply
SqueezeRib
SqueezeRib Jul. 9 at 5:32 PM
$KZIA Run the turd back
0 · Reply
Dpock23
Dpock23 Jul. 9 at 4:25 PM
$KZIA PHH ready to go! 🚀🚀
0 · Reply
scottpetet
scottpetet Jul. 9 at 3:58 PM
$KZIA Who listened? And who didn’t?
0 · Reply
LewisDaKat
LewisDaKat Jul. 9 at 3:55 PM
News out Kazia Therapeutics Reports Positive Initial Phase 1b Trial Data from First Triple-Negative Breast Cancer Patient Treated with Paxalisib Combination Regimen https://marketwirenews.com/news-releases/kazia-therapeutics-reports-positive-initial-phase-1b-6899924246030084.html $KZIA
0 · Reply
jaytradingdesk
jaytradingdesk Jul. 9 at 3:45 PM
$CLDI $SUGP $KZIA $EVOK Market hasn’t even opened yet and we’re already banking with the community. Entries, stop losses and targets mentioned.
0 · Reply
intrader
intrader Jul. 9 at 3:42 PM
$KZIA I'm out.
1 · Reply
intrader
intrader Jul. 9 at 3:40 PM
$KZIA In with size.
0 · Reply
gaboriar
gaboriar Jul. 9 at 3:37 PM
$KZIA $11 / share meets Nasdaq MC min? $15M
1 · Reply
MIMI133
MIMI133 Jul. 9 at 3:36 PM
0 · Reply
minazeem
minazeem Jul. 9 at 3:28 PM
0 · Reply
MoneyPennyStocks
MoneyPennyStocks Jul. 9 at 3:15 PM
$KZIA Gap fill and then bounce back to 10.35.
0 · Reply